Spotlight
Specialty
Partners
CME/CE
Diagnosis and Treatment of Metastatic Colorectal Cancer With a Focus on HER2-Positive Disease : Episode 15
Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials
Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.
EP: 1.Overview of Molecular Testing in Metastatic Colorectal Cancer (mCRC)
EP: 2.Role of Tissue Versus Circulating Tumor DNA in Molecular Testing in mCRC
EP: 3.Circulating Tumor DNA to Guide Treatment Selection for mCRC
EP: 4.Challenges With Molecular Testing in Metastatic Colorectal Cancer
EP: 5.First-Line Treatment Options for mCRC
EP: 6.Trastuzumab Deruxtecan in HER2+ mCRC
EP: 7.HER2+ mCRC: Managing Adverse Events Associated With Antibody Drug Conjugates
EP: 8.Role of Tucatinib in HER2+ mCRC
EP: 9.Importance of Identifying HER2 Status in Metastatic Colorectal Cancer
EP: 10.Combination Therapy in BRAF-Mutated mCRC: The BEACON CRC Trial
EP: 11.Combination Therapy in BRAF-Mutated mCRC: The BREAKWATER Trial
EP: 12.Other Combination Strategies in BRAF-Mutated Metastatic Colorectal Cancer
EP: 13.Clinical Trials in Metastatic Colorectal Cancer: Combination IO Therapy
EP: 14.Combination IO/TKI Strategies in Metastatic Colorectal Cancer
Now Viewing
EP: 15.Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials
EP: 16.Metastatic Colorectal Cancer: Future Directions in Care
Related Videos
Related Content
